High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults
Authors:
- Marie‐Cécile Le DeleyMDMarie‐Cécile Le Deley
- Akthar ShamsaldinASAkthar Shamsaldin
- 28 March 2005
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 45 (1) , 25-31
Abstract
Background: In a national pediatric case‐control study, we observed a very high relative risk of leukemia in patients who had received continuous etoposide (CE) over 6 months or more, but we could not estimate the absolute risk. The purpose of the present study was to estimate this absolute risk after CE.Procedures: We report a study of 18 patients with refractory or recurrent tumors who received CE over 6 months or more between 1995 and 1997. It was administered either 3 days a week for 3/4 weeks (“3 × 3”, 14 patients) or 7 days a week for 3/4 weeks (“7 × 3”, four patients).Results: Five patients developed secondary leukemia 10–25 months after the initiation of CE. All the others died of their first tumor. The cumulative incidence of leukemia at 30 months was 28% (95% CI, 10%–53%). A chromosome 11q23 rearrangement was found in 3/5 cases. All four patients who received the “7 × 3” CE schedule developed leukemia compared to 1/14 treated with the “3 × 3” CE schedule (P = 0.002).Conclusions: Given its efficacy, CE may still have a place as a palliative treatment. However, the risk of leukemia must be borne in mind when considering its use in patients with a better prognosis. Pediatr Blood Cancer 2005; 45:25–31.Keywords
This publication has 27 references indexed in Scilit:
- Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d’Oncologie PédiatriqueJournal of Clinical Oncology, 2003
- Two secondary leukemias among 15 children given oral etoposideMedical and Pediatric Oncology, 2001
- SECONDARY LEUKEMIA IN A CHILD WITH NEUROBLASTOMA WHILE ON ORAL ETOPOSIDE: What is the Cause?Pediatric Hematology and Oncology, 2000
- Prolonged Oral Etoposide in Recurrent or Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group StudyGynecologic Oncology, 1998
- Phase II study of 21 day schedule oral etoposide in childrenEuropean Journal of Cancer, 1997
- Relationship Between Cytotoxicity and Site-Specific DNA Recombination After In Vitro Exposure of Leukemia Cells to EtoposideJNCI: Journal of the National Cancer Institute, 1996
- Estimation of the radiation dose delivered to any point outside the target volume per patient treated with external beam radiotherapyRadiotherapy and Oncology, 1996
- Phase II study of rapid-scheduled etoposide in paediatric soft tissue sarcomasEuropean Journal of Cancer, 1995
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- Active bone marrow distribution as a function of age in humansPhysics in Medicine & Biology, 1981